SLM Corporation - Floating Rate Non-Cumulative Preferred Stock, Series B (SLMBP)
Live price chart, market sentiment, and community perspectives for SLM Corporation - Floating Rate Non-Cumulative Preferred Stock, Series B (NASDAQ: SLMBP).
Live price chart, market sentiment, and community perspectives for SLM Corporation - Floating Rate Non-Cumulative Preferred Stock, Series B (NASDAQ: SLMBP).
On our desk, the valuation picture for SLMBP is quite nuanced. While TrendMatrix flags the preferred shares trading above intrinsic value with a SELL verdict due to limited capital appreciation upside, the underlying income safety remains exceptionally strong with a massive dividend coverage ratio. However, investors need to weigh this against the recent Q2 2026 earnings miss where EPS dropped to $0.29 against expectations of $0.44. Market sentiment is reacting cautiously to these bottom-line headwinds despite firm recent price action in the broader equity.
From a quantitative and technical standpoint, SLMBP has been operating inside a 52-week range between $72 and $78, currently hovering around $74.86. Although 15 Wall Street analysts project a mean consensus price target of $85.08—implying roughly 14% upside—short-term target revisions have trended downwards by over 16% to 19% over the past 1 to 3 months. Analysts underwriting preferred issuances must reconcile the stellar Q1 EPS beat of $1.54 against the subsequent Q2 miss when modeling capital stability.
Looking at the risk factors disclosed in the latest 10-K filings, the primary concentration exposure for SLM Corporation remains centered on Private Education Loans. Recent updates from August 2026 show a month-over-month increase in on-balance-sheet delinquencies alongside shifting net charge-offs, which Morgan Stanley analysts note could challenge consensus forecasts for the second half of the year. Combined with student loan reform narratives, risk management protocols suggest monitoring credit quality shifts closely before committing fresh capital.
Explore plasma cleansing, somatic organ swaps, and BCI.